MEI Pharma Inc expected to post a loss of $1.52 a share - Earnings Preview

Lite Strategy

07/05/2024 12:24

* MEI Pharma Inc  MEIP.OQ   MEIP.O  is expected to show a
fall in
quarterly revenue when it reports  results on May 9 (estimated)
for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
99.4% decrease in revenue to $37.5 thousand from $5.89 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for MEI Pharma Inc is for a
loss
of $1.52 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MEI Pharma
Inc is
$20.00​, above​ its last closing price of $3.20. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.33       -1.32      -1.66     Missed  -25.3
 Sep. 30 2023  -2.12       -2.12      8.46      Beat    499.1
 Jun. 30 2023              -2.41      -1.51     Beat    37.5​
 Mar. 31 2023  -2.78       -2.87      -2.32     Beat    19.1
 ​​Dec.        -3.03       -3.00      1.60      Beat    153.3
 31 2022                                                
 Sep. 30 2022  -2.86       -2.87      -2.40     Beat    16.3​
 Jun. 30 2022  -3.55       -3.71      -2.40     Beat    35.4
 Mar. 31 2022  -3.53       -3.65      -1.40     Beat    61.6
 This summary was machine generated May 7 at 11:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)